{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:24:53Z","timestamp":1787023493576,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hormonal therapy and chemotherapy are common systemic therapy options in advanced and recurrent endometrial cancer. There is limited consensus on factors that affect therapy selection. This study aims to gain insight into those factors at the level of clinical decision-making and at the level of patient- and tumor-specific factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed an international cross-sectional study among medical oncologists and gynecologists. The survey consisted of (1) statements about barriers and facilitators that affect the process of decision-making and (2) hypothetical vignette cases investigating three patients and tumor factors that were tested with three levels each. Results were analyzed with descriptive statistics and linear mixed-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>167 physicians responded to the survey. The most important facilitating factors were: understanding the patient\u2019s personal context and the role of multidisciplinary tumor board discussions. The most important barrier was the lack of evidence for prediction of response to hormonal therapy and chemotherapy. The three patient and tumor factors included in the vignette cases were severity of symptoms, performance status, and progesterone-receptor (PR) expression in the tumor. PR expression and performance status were most discriminative, with high PR expression and poor performance status favoring hormonal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The provision of personalized care in palliative treatment of endometrial cancer can be improved by multidisciplinary tumor board discussions with the personal context and preference of the patient in mind. The patient factors, severity of symptoms and WHO performance status, and the tumor factor, PR tumor expression, were most relevant for selecting hormonal therapy or chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-026-08486-0","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:56:47Z","timestamp":1781236607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hormonal therapy or chemotherapy for advanced endometrial cancer? A mixed-methods study assessing physicians\u2019 attitudes"],"prefix":"10.1007","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-9556","authenticated-orcid":false,"given":"Willem Jan","family":"van Weelden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mesu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella B.","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.A.","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna W.M.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"3","key":"8486_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"8486_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00428-020-03007-z","volume":"478","author":"N Concin","year":"2021","unstructured":"Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch 478(2):153\u2013190","journal-title":"Virchows Arch"},{"issue":"2","key":"8486_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","volume":"21","author":"N Abu-Rustum","year":"2023","unstructured":"Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R et al (2023) Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(2):181\u2013209","journal-title":"J Natl Compr Canc Netw"},{"issue":"33","key":"8486_CR4","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1200\/JCO.20.01076","volume":"38","author":"DS Miller","year":"2020","unstructured":"Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS et al (2020) Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209). J Clin Oncol 38(33):3841\u20133850","journal-title":"J Clin Oncol"},{"issue":"2","key":"8486_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ygyno.2008.01.028","volume":"109","author":"D Pectasides","year":"2008","unstructured":"Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A et al (2008) Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 109(2):250\u2013254","journal-title":"Gynecol Oncol"},{"issue":"4","key":"8486_CR6","doi-asserted-by":"publisher","first-page":"407 e1","DOI":"10.1016\/j.ajog.2021.05.007","volume":"225","author":"WJ van Weelden","year":"2021","unstructured":"van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H et al (2021) Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. Am J Obstet Gynecol 225(4):407 e1-e16","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"8486_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ygyno.2017.07.002","volume":"147","author":"JL Ethier","year":"2017","unstructured":"Ethier JL, Desautels DN, Amir E, MacKay H (2017) Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol 147(1):158\u201366","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8486_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13058-z","volume":"24","author":"D Huang","year":"2024","unstructured":"Huang D, Li S, Bai Y, Wang Y (2024) Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis. BMC Cancer 24(1):1298","journal-title":"BMC Cancer"},{"issue":"3","key":"8486_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1470-2045(23)00016-5","volume":"24","author":"S Pignata","year":"2023","unstructured":"Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D et al (2023) Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 24(3):286\u201396","journal-title":"Lancet Oncol"},{"issue":"11","key":"8486_CR10","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1136\/ijgc-2024-005541","volume":"34","author":"S Huepenbecker","year":"2024","unstructured":"Huepenbecker S, Meyer LA, Craft M, Chan JK, Craggs C, Lambert P et al (2024) Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Int J Gynecol Cancer 34(11):1719\u201328","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"8486_CR11","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB et al (2023) Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 388(23):2159\u201370","journal-title":"N Engl J Med"},{"issue":"17","key":"8486_CR12","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1200\/JCO.2002.12.012","volume":"20","author":"CG Koedoot","year":"2002","unstructured":"Koedoot CG, De Haes JC, Heisterkamp SH, Bakker PJ, De Graeff A, De Haan RJ (2002) Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol 20(17):3658\u201364","journal-title":"J Clin Oncol"},{"issue":"10","key":"8486_CR13","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.pec.2015.06.022","volume":"98","author":"AM Stiggelbout","year":"2015","unstructured":"Stiggelbout AM, Pieterse AH, De Haes JC (2015) Shared decision making: concepts, evidence, and practice. Patient Educ Couns 98(10):1172\u20139","journal-title":"Patient Educ Couns"},{"issue":"1","key":"8486_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1186\/s12913-022-08112-0","volume":"22","author":"JEW Walraven","year":"2022","unstructured":"Walraven JEW, van der Hel OL, van der Hoeven JJM, Lemmens V, Verhoeven RHA, Desar IME (2022) Factors influencing the quality and functioning of oncological multidisciplinary team meetings: results of a systematic review. BMC Health Serv Res 22(1):829","journal-title":"BMC Health Serv Res"},{"key":"8486_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ctrv.2015.11.007","volume":"42","author":"B Pillay","year":"2016","unstructured":"Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P et al (2016) The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev 42:56\u201372","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"8486_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","volume":"1","author":"HG Prigerson","year":"2015","unstructured":"Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ et al (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1(6):778\u201384","journal-title":"JAMA Oncol"},{"issue":"2","key":"8486_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/1471-0528.17331","volume":"130","author":"WJ van Weelden","year":"2023","unstructured":"van Weelden WJ, Birkendahl PB, Lalisang RI, IntHout J, Kruitwagen R, Romano A et al (2023) The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta-analysis. BJOG 130(2):143\u201352","journal-title":"BJOG"},{"key":"8486_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3389\/fonc.2019.00359","volume":"9","author":"WJ van Weelden","year":"2019","unstructured":"van Weelden WJ, Massuger L, Pijnenborg JMA, Romano A (2019) Anti-estrogen treatment in endometrial cancer: a systematic review. Front Oncol 9:359","journal-title":"Front Oncol"},{"issue":"8","key":"8486_CR19","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","volume":"26","author":"N Concin","year":"2025","unstructured":"Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, Ledermann J et al (2025) ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol 26(8):e423\u2013e35","journal-title":"Lancet Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08486-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08486-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08486-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:37:53Z","timestamp":1787020673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08486-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8486"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08486-0","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. The Radboudumc Institutional Review Board approved the study (approval number 2017-3803).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Respondents provided consent for participation in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"254"}}